Menu

Huge Gender Disparity in Cancer Research Funding in U.K.

Men received both more and larger grants than women did, ending up with three times as much funding on average.

May 16, 2018
Shawna Williams

ISTOCK, TSVIBRAVBetween 2000 and 2013, women received just 31 percent of the number of cancer research grants awarded in the U.K., and 22 percent of the total funds to investigate cancer, according to an analysis published Tuesday (May 14) in BMJ Open. “We would strongly urge policy-makers, funders and the academic and scientific community to investigate the factors leading to our observed differences and seek to ensure that women are appropriately supported in scientific endeavour,” the authors write in the paper.

The analysis examined data on both public and philanthropic grants given to support cancer research in the U.K. Male PIs were awarded 69 percent of the grants, and their grants were on average 1.3 times as large as those given to women, so that they received 78 percent of the total money allocated.

“The significant concern following such an apparent gender imbalance is the possibility of bias or inequality against women researchers, which must be addressed,” coauthor Mahiben Maruthappu tells Medscape Medical News.

Gender disparities in the sciences are well-established. For example, female PhD students tend to publish less than their male counterparts and women are less likely to have opportunities to speak at conferences or to be successful when applying for patents. The authors of the paper note that “just one in five countries worldwide has achieved gender parity in scientific research (defined as when 45% to 55% of researchers are women).”

January 2019

Cannabis on Board

Research suggests ill effects of cannabinoids in the womb

Marketplace

Sponsored Product Updates

FORMULATRIX® digital PCR technology to be acquired by QIAGEN
FORMULATRIX® digital PCR technology to be acquired by QIAGEN
FORMULATRIX has announced that their digital PCR assets, including the CONSTELLATION® series of instruments, is being acquired by QIAGEN N.V. (NYSE: QGEN, Frankfurt Stock Exchange: QIA) for up to $260 million ($125 million upfront payment and $135 million of milestones).  QIAGEN has announced plans for a global launch in 2020 of a new series of digital PCR platforms that utilize the advanced dPCR technology developed by FORMULATRIX combined with QIAGEN’s expertise in assay development and automation.
Application of CRISPR/Cas to the Generation of Genetically Engineered Mice
Application of CRISPR/Cas to the Generation of Genetically Engineered Mice
With this application note from Taconic, learn about the power that the CRISPR/Cas system has to revolutionize the field of custom mouse model generation!
Translational Models of Obesity, Dysmetabolism, Diabetes, and Complications
Translational Models of Obesity, Dysmetabolism, Diabetes, and Complications
This webinar, from Crown Bioscience, presents a unique continuum of translational dysmetabolic platforms that more closely mimic human disease. Learn about using next-generation rodent and spontaneously diabetic non-human primate models to accurately model human-relevant disease progression and complications related to obesity and diabetes here!
BiochemAR: an augmented reality app for easy visualization of virtual 3D molecular models
BiochemAR: an augmented reality app for easy visualization of virtual 3D molecular models
Have you played Pokemon Go? Then you've used Augmented Reality (AR) technology! AR technology holds substantial promise and potential for providing a low-cost, easy to use digital platform for the manipulation of virtual 3D objects, including 3D models of biological macromolecules.